Here's Why Cellectar Biosciences Shares Are Rising

Cellectar Biosciences Inc CLRB shares are trading higher by 12.1% at $0.61 after the company reported better-than-expected fourth-quarter EPS results. Cellectar Biosciences beat estimated earnings by 10.0%, reporting an EPS loss of 9 cents versus an estimate of a loss of 10 cents.

"The data presented from our ongoing trials continue to be very encouraging, and we believe iopofosine has the potential to provide a meaningful therapeutic benefit for patients with Waldenstrom's macroglobulinemia (WM) and other treatment refractory B-cell lymphomas. We continue to make significant strides in our clinical trials as we enroll patients in our ongoing pivotal trial in WM and our Phase 2 CLOVER-1 study," said James Caruso, president and CEO of Cellectar.

"We look forward to sharing our planned interim data safety monitoring assessment from our WM pivotal trial. In the near-term our efforts are supported by a strong balance sheet that will fund our expected clinical and regulatory milestones into the second half of 2023," Caruso added.

Cellectar Biosciences is a clinical stage biopharmaceutical company. It focusses on the development of targeted phospholipid drug conjugates for the treatment and imaging of cancer.

Cellectar Biosciences has a 52-week high of $2.09 and a 52-week low of $0.44.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Penny StocksMoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!